Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Ping An-Affiliated Fintech Firm OneConnect Raises Capital from New Share Sale As It Eyes Global Expansion
Pompeo Hints At ‘Broader’ Ban on Chinese Apps After Trump’s Executive Orders Targeting TikTok and WeChat
Trending in China: Merchants and Netizens Forced to Pick Sides in Fight Between Delivery Firms
Baidu-Backed Video Streamer iQiyi Probed by U.S. Regulator After Short Seller’s Report
AI Unicorn SenseTime Is Said to Mull Hong Kong, China IPO
Huawei Copies Korean Rivals by Manufacturing Own Display Driver Integrated Chips
JOYY’s Livestreaming Revenue Up 40% in Second Quarter of 2020
Trending in China: ‘Mukbangs’ Under Fire in China Amid High Level Food Waste Campaign
Trending in China: How Will the Chinese Diaspora Survive a WeChat Ban In U.S.?
Online Platform JD.com Buys into Bricks and Mortar Convenience Store Chain
China Unicom Profits Rise in First Half, Stock Soars
ByteDance in Talks with Indian Conglomerate Over TikTok Amid Layoff Fears
Alibaba’s Zhang Yong Tops 2020 Forbes China Best CEOs List
Trending: Family Feud Raises Big Questions Over Succession in China’s Multi-Million “Family” Businesses
Shanghai-Listed Foxconn Internet’s Cloud Service Sales Up 4% in First Half of 2020
U.S.-Listed Chinese Companies Nio and Huya Have Something to Cheer About
Apple Edges Huawei Out of No. 1 in Quarterly Tablet Shipments
Chinese Finance Platform Lufax Files for U.S. IPO of up to $3 Billion
China Mainland Leads U.S. in Fortune Global 500 Companies But Trails in Profitability
Trending in China: Tencent – Fighting Youth Unemployment or Enemy of Older Workers?
Biopharma Firm SinoMab BioScience Files $223 million IPO in Hong Kong

By Liu Yanfei and Denise Jia / Oct 31, 2019 04:23 AM / Finance

Photo: VCG

Photo: VCG

Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd. plans to raise as much as HK$1.75 billion ($223 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.

Chinese pharmaceutical company Yunnan Baiyao Group Co. as a cornerstone investor pledged to subscribe for $50 million of shares in the IPO.

SinoMab plans to offer a total of 182 million shares globally, 10% of them in Hong Kong and the rest elsewhere. The offering price will range between HK$7.60 and HK$9.60 a share, according to the prospectus.

The company will start an international roadshow Wednesday; the public offering will begin Thursday; and the shares are scheduled to list Nov. 12.

SinoMab develops therapies for immunological diseases, primarily monoclonal antibody-based biologics, or those that use the body's immune system to attack disease-causing cells.

The company’s flagship product, called SM03, is intended to treat rheumatoid arthritis and is being evaluated in a late-stage study. The company expects to complete the clinical trial and submit a new drug application by mid 2020, the company’s founder and Chief Executive Liang Ruian said Wednesday at a press conference.

The startup doesn’t have any commercialized products or operating revenue. It recorded a net loss of 83.61 million yuan in 2018.

China International Capital Corp. and Orient Securities serve as joint sponsors of the IPO.

Contact reporter Denise Jia (huijuanjia@caixin.com)

Share this article
Open WeChat and scan the QR code